Recruiting in China · live from ClinicalTrials.gov
Proton therapy trials in China
Proton therapy delivers radiation with millimeter precision, sparing healthy tissue around the tumor — an advantage for cancers near critical structures and for pediatric patients. China's proton capacity is expanding quickly across a growing set of centers, frequently at a fraction of US pricing.
The studies below are recruiting now, pulled live from the public ClinicalTrials.gov registry. If you're weighing proton therapy abroad, we can help you understand which programs match your diagnosis.
12 proton therapy trials recruiting
Each card links to full eligibility criteria and study locations. Not sure which fit? Ask Nora in the chat, or request a free review below.
Effect of PPIs on Stool DNA Test for H. Pylori
Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer
To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC
Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
Want help narrowing these down?
Send your diagnosis and treatment history and a coordinator will identify the proton therapy trials you may actually qualify for — free, within 24 hours.
We share your details only with vetted treatment coordinators to check trial eligibility. No spam. See our privacy note.